

Special Issue

Evaluating the Immune Response to RNA Vaccine

Message from the Guest Editors

RNA technology has demonstrated numerous advantages in vaccine development and is widely recognized for its versatility. Specifically, it can be utilized in the development of new vaccines or therapeutics for various types of infectious or non-infectious diseases by manipulating the mRNA cargo and the lipid-based delivery system. However, we still lack a comprehensive understanding of how these vaccines work, particularly regarding their interactions with the immune system and the underlying mechanism of action implicated in the generation of high-quality vaccine responses. In this Special Issue, we seek original research articles and review articles that address the immune mechanisms of RNA vaccines. This includes, but is not limited to, innate immune signatures, the magnitude and quality of antibody responses, and the regulation of B cell and T cell compartments. These investigations provide essential guidance for the rational design of RNA vaccines.

Guest Editors

Dr. Ang Lin

Center for infectious medicine and vaccine research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China

Dr. Huajun Zhao

School of Pharmaceutical Sciences, Shandong University, Jinan, China

Deadline for manuscript submissions

closed (31 March 2026)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/210841

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).